AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00191282
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine injected subcutaneous (SC) once daily in the evening until patient completes study.
Trial: NCT03152955
Drug: ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron(13ug/kg/h) is applied in patient-controlled analgesia.
Trial: NCT01498822
Drug: Levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 250 mg and 500 mg Levetiracetam tablet, 1000 mg-3000 mg/day, maximum 50 weeks including initial up titration of 500 mg/day for 2 weeks
Trial: NCT01609816
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients receive dasatinib PO every day (QD) for 6 months.
Trial: NCT00994708
Drug: esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02889900
Drug: cediranib and olaparib
RxNorm normalized name: Olaparib
DrugBank: Cediranib (DB04849)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cediranib tablets oral dose 30 mg once daily; Olaparib(Lynparza) tablet 200 mg twice daily~Dose reduction for both products is allowed
Trial: NCT00881491
Drug: Mineral Trioxide Aggregate
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard material providing an apical barrier
Trial: NCT00352092
Drug: sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00352092
Drug: mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02561494
Drug: Nefopam
RxNorm normalized name: nefopam
DrugBank: Nefopam (DB12293)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02561494
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00242372
Drug: Tesaglitazar 0.5
DrugBank: Tesaglitazar (DB06536)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05125575
Drug: Metformin 1000 mg Prolonged Release Tablets (JSC Farmak, Ukraine)
RxNorm normalized name: metformin 1000 MG
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: One tablet of the Test (T) product was administered orally with 240 mL of water.
Trial: NCT00361439
Drug: Mometasone
RxNorm normalized name: Mometasone
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 puffs in each nostril once daily of nasal spray
Trial: NCT03999697
Drug: Autologous chimeric antigen receptor T cell transfusing agent targeting CD22
RxNorm normalized name: Autologous bi-epitope BCMA-targeted CAR T-cells
DrugBank: Ciltacabtagene autoleucel (DB16738)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The enrolled patients will receive autologous-derived CD22-targeted CAR-T cells in 1 day with 100% of the total expected dosage after receiving lymphodepleting chemotherapy
Trial: NCT02809105
Drug: linaclotide
RxNorm normalized name: Linaclotide
DrugBank: Linaclotide (DB08890)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral administration once daily
Trial: NCT03204955
Drug: Sodium chloride /sodium acetate (16.4%)
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium Acetate is a sterile, nonpyrogenic solution of Sodium Acetate intended as an alternative to sodium chloride to provide sodium ion in parenteral (IV) fluid therapy.~Sodium Chloride is sterile, nonpyrogenic hypertonic saline (concentrated sodium-chloride) solution for parenteral (IV) fluid therapy.
Trial: NCT03204955
Drug: Sodium chloride (23.4%)
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium Chloride is sterile, nonpyrogenic hypertonic saline (concentrated sodium-chloride) solution for parenteral (IV) fluid therapy.
Trial: NCT01855997
Drug: Peg-IFN alfa-2a
RxNorm normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received Peg-IFN alfa-2a prior to enrollment for at least 24 weeks. Dosing was chosen according to standard of care or at the discretion of the treating physician.
Trial: NCT01225705
Drug: raltegravir
RxNorm normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will be randomized 1:1 to either the experimental or the active control arm
Trial: NCT01225705
Drug: Atazanavir/ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will be randomized 1:1 to either the experimental or the active control arm
Trial: NCT02461719
Drug: Restasis
RxNorm normalized name: Restasis
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop twice/day for 12 weeks to both eyes. Invert the unit dose vial a few times to obtain a uniform, white, opaque emulsion before using.
Trial: NCT03677323
Drug: Droleptan
DrugBank: Droperidol (DB00450)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Venous administration of 1.25 mg of Droleptan
Trial: NCT03677323
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Venous administration of 20 mg of Propofol
Trial: NCT03677323
Drug: Sufentanyl
RxNorm normalized name: Sufentanyl
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Venous administration of 5 μg of Sufentanyl.
Trial: NCT03566303
Drug: Rivaroxaban 15 mg
RxNorm normalized name: rivaroxaban 15 MG
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban 15 mg BID
Trial: NCT03566303
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Warfarin
Trial: NCT00000605
Drug: hormone replacement therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000605
Drug: estrogens
RxNorm normalized name: estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000605
Drug: medroxyprogesterone
RxNorm normalized name: Medroxyprogesterone
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02580227
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All subjects will be given 1g of TXA in 100cc normal saline, or placebo of 100cc normal saline at time of admission, after consent is given.
Trial: NCT02805426
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02805426
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01623609
Drug: Naloxegol
RxNorm normalized name: Naloxegol
DrugBank: Naloxegol (DB09049)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Naloxol IR tablet 25 mg (naloxegol oxalate) commercial formulation
Trial: NCT02836236
Drug: TDF
RxNorm normalized name: moxetumomab pasudotox-tdfk
DrugBank: Moxetumomab pasudotox (DB12688)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: TDF 300 mg tablet administered orally once daily
Trial: NCT00246987
Drug: Muraglitazar
RxNorm normalized name: Muraglitazar
DrugBank: Muraglitazar (DB06510)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00290134
Drug: Fispemifene once daily for 4 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Fispemifene (DB06640)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03714334
Drug: DNX-2440 injection
RxNorm normalized name: Ad5-DNX-2401
DrugBank: Tasadenoturev (DB17178)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNX-2440 virus will be injected stereotactically
Trial: NCT02287285
Drug: Exendin9
RxNorm normalized name: Exendin 4
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosed at 600 pmol/kg/min for 210 minutes.
Trial: NCT01106677
Drug: Canagliflozin
RxNorm normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One 100 mg or 300 mg over-encapsulated tablet orally once daily for 52 weeks with protocol-specified doses of metformin immediate release.
Trial: NCT01623609
Drug: Naloxegol
RxNorm normalized name: Naloxegol
DrugBank: Naloxegol (DB09049)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Naloxegol film-coated Phase III formulation 25 mg film-coated IR tablet
Trial: NCT00005635
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01106677
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: One 100 mg over-encapsulated tablet orally once daily for 52 weeks (sitagliptin 100 mg arm) or once daily beginning at Week 26 until Week 52 (placebo/sitagliptin arm). Sitagliptin will be given with protocol-specified doses of metformin immediate release.
Trial: NCT01106677
Drug: Metformin immediate release
RxNorm normalized name: metformin Extended Release Suspension
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The patient's stable dose of metformin immediate release background therapy should be continued throughout the study.
Trial: NCT01163214
Drug: Periarticular Injection
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Periarticular local injection into the periarticular soft tissues at the time of knee replacement using a combination of ropivacaine, epinephrine, ketorolac, and morphine sulphate. Subjects in this arm received the injection combination based on three subject weight categories.
Trial: NCT01654601
Drug: DWCZP
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Multiple dose
Trial: NCT01654601
Drug: Clozaril
RxNorm normalized name: Clozaril
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: multiple-dose
Trial: NCT01119898
Drug: PENNSAID Gel
RxNorm normalized name: Pennsaid
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks
Trial: NCT03360916
Drug: Lipitor 20Mg Tablet
RxNorm normalized name: Lipitor 20mg Tablet
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One tablet by mouth every day for 12 weeks.
Trial: NCT03360916
Drug: Lipitor 80Mg Tablet
RxNorm normalized name: Lipitor 80mg Tablet
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One tablet by mouth every day for 12 weeks.
Trial: NCT03431649
Drug: Beraprost Sodium
RxNorm normalized name: beraprost sodium
DrugBank: Beraprost (DB05229)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mcg /kgbw daily, divided in three dosages orally for 12 weeks
Trial: NCT03431649
Drug: Sildenafil Citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.4 mg/kgbw each time, 4 times in a day orally for 12 weeks
Trial: NCT01631409
Drug: Aspirin, Isosorbide mononitrate, Atenolol, Enalapril.
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the course of optimal medical treatment of Cohort I patient the life style modification is combined with one group of antianginal medications (e.g. Nitrates, Beta-blockers, ACE inhibitors, Calcium antagonists) and lipid-lowering drugs (e.g. HMG-CoA reductase inhibitors).
Trial: NCT01631409
Drug: Aspirin, Isosorbide mononitrate, Atenolol, Enalapril.
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the course of maximal antianginal medical therapy a Cohort II patient is provided with more than one group of antianginal medications (e.g. Nitrates, Beta-blockers, ACE inhibitors, Calcium antagonists) combined with lowering-lipid drugs (e.g. HMG-CoA reductase inhibitors).
Trial: NCT01739218
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin will be administered at a dose calculated according to the Calvert formula (\[participant's glomerular filtration rate + 25\] multiplied by the target area under the concentration-time curve \[AUC\] of 5 milligrams per milliliter per minute \[mg/mL/min\]), as intravenous \[IV\] infusion over 30-60 minutes \[min\] every 3 weeks).
Trial: NCT01739218
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel will be administered at a dose of 175 milligrams per meter-squared \[mg/m\^2\] as IV infusion over 3 hours using a rate controlling device every 3 weeks, or at a dose of 80 mg/m\^2 as IV infusion over 1 hour using a rate controlling device every week (only during Cycles 5 to 8).
Trial: NCT01631409
Drug: Aspirin, Isosorbide mononitrate, Atenolol, Enalapril
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the course of maximal antianginal medical therapy a Cohort VI patient is provided with more than two groups of antianginal medications (e.g. Nitrates, Beta-blockers, ACE inhibitors, Calcium antagonists) combined with lowering-lipid drugs (e.g. HMG-CoA reductase inhibitors).
Trial: NCT01786876
Drug: Radiolabeled SPD557
RxNorm normalized name: Radiolabelled DUNP19
DrugBank: RAD 502 (DB17328)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of 2 mg radiolabeled SPD557 administered on Day 1
Trial: NCT00241618
Drug: Pegylated interferon alpha 2
RxNorm normalized name: Pegylated interferon alpha-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00241618
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01072045
Drug: Propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral propranolol, at a dose of 2mg/kg/day, divided in 2 doses, for initial 60 days
Trial: NCT01072045
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone, at a dose of 2mg/kg/day, divided in 2 doses, for initial 60 days
Trial: NCT01739218
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab will be administered at a dose of 15 milligrams per kilogram \[mg/kg\] as IV infusion over 30-90 min every 3 weeks.
Trial: NCT02240927
Drug: Enoxaparine and 4mg Warfarin
RxNorm normalized name: warfarin sodium 4 MG
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If the patient's warfarin consumption dose is more than 5 mg before pregnancy, warfarin dose is decreased to 4 mg during the first trimester and combined with enoxaparine in 1mg/kg dose twice a day. Enoxaparine dose is adjusted according to anti-factor Xa levels (between 0.5-1). Full dose warfarin is continued after first trimester and dose is regulated according to INR level (between 2.5-4).
Trial: NCT02240927
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If the patient's therapeutic warfarin dose is less than 5 mg before pregnancy, warfarin is continued in the same dose during all the pregnancy and the dose is adjusted according to INR level (between 2.5-4).
Trial: NCT03397329
Drug: AG-348 Sequence A
RxNorm normalized name: ANTIHEMOPHILIC FACTOR (RECOMBINANT), PORCINE SEQUENCE
DrugBank: Susoctocog alfa (DB11606)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: 1. Treatment Period 1 Single 50 mg dose of AG-348 administered as a capsule formulation (2 × 25 mg capsules)~2. Washout Period 7 days~3. Treatment Period 2 Single 50 mg dose of AG-348 administered as a tablet formulation (1 × 50 mg tablet)
Trial: NCT01159236
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 80 mg/m2 by vein over about 1-2 hours once every 7 days x 12 courses.
Trial: NCT01159236
Drug: Epirubicin
RxNorm normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg/m2 by vein given on day 1 and repeated once every 21 days for 4 treatments, may be given instead of Doxorubicin in Group 1 and 2.
Trial: NCT01159236
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 mg/kg intravenously every 2 weeks, discontinued 6 weeks before surgery (i.e. after 3rd course of FEC or FAC)
Trial: NCT00776113
Drug: Carvedilol 12.5 mg tablets
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bioequivalence Carvedilol fasting
Trial: NCT01865201
Drug: Edaravone
RxNorm normalized name: Edaravone
DrugBank: Edaravone (DB12243)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Be used at a dose of 30mg, intravenously, twice per day, for 14 days.
Trial: NCT01084200
Drug: Propofol for maintenance
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 6-8mg/kg/h + Remifentail 0.1-0.2ug/kg/min for anesthesia maintenance
Trial: NCT01084200
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane 0.7-1.3MAC + Remifentail 0.1-0.2ug/kg/min for anesthesia maintenance
Trial: NCT01084200
Drug: Sevoflurane+Propofol
RxNorm normalized name: Sevoflurane
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane 0.7-1.3MAC + Remifentanil 0.1-0.2ug/kg/min + Propofol 2mg/kg/h for anesthesia maintenance
Trial: NCT00545246
Drug: aflibercept (AVE0005)
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravenous infusion
Trial: NCT00545246
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous infusion
Trial: NCT02311413
Drug: Cat-PAD
RxNorm normalized name: cat hair extract
DrugBank: Felis catus hair (DB10499)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The assigned study intervention will be administered by intradermal injection into the flexor surface of the forearm.
Trial: NCT00529204
Drug: exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects meeting the inclusion criteria will be treated with exenatide 5 µg BID s.c. for 3-7 days, followed by 10 µg BID s.c. daily to week 24
Trial: NCT03138252
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02129101
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given SC or IV
Trial: NCT02129101
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02129101
Drug: Sonidegib
RxNorm normalized name: Sonidegib
DrugBank: Sonidegib (DB09143)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT01122381
Drug: ethosuximide
RxNorm normalized name: Ethosuximide
DrugBank: Ethosuximide (DB00593)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ethosuximide (ESX)
Trial: NCT03917784
Drug: Curcumin
RxNorm normalized name: Curcumin
DrugBank: Curcumin (DB11672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral supplementation with curcumin 500 mg oral dosing for 3 months
Trial: NCT03917784
Drug: Starch
RxNorm normalized name: Starch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral supplementation with starch 500 mg oral dosing for 3 months
Trial: NCT02174887
Drug: Nab-paclitaxel + Gemcitabine
RxNorm normalized name: Paclitaxel
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Gemcitabine 1 g/m² IV infusion over 30 minutes at D1-D8-D15 every 28 days in combination with Nab-paclitaxel 125 mg/m² IV infusion over 30 minutes at D1-D8-D15 every 28 days~The patients will receive 2 cycles of treatment every 28 days:
Trial: NCT00661739
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose-level Bendamustine(mg/m²): I:50; II:60; III:60; IV:70; V:70 Dose-level Paclitaxel (mg/m²): I:60; II:60; III:80; IV:80; V:90 Treatment will be given on day 1,8,15 and repeated on day 29. When the recommended dose has been determined a total of 48 pts will be treated at this dose level.
Trial: NCT00941798
Drug: Mometasone Twisthaler®
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily via multi-dose dry-powder inhaler
Trial: NCT04092725
Drug: DAB
RxNorm normalized name: aDabi-Fab
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single oral 150-mg dose of DAB on Day 1 AM.
Trial: NCT03272659
Drug: Cysview
RxNorm normalized name: Cysview
DrugBank: Hexaminolevulinate (DB06261)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mL enema containing 1.6 mmol of hexaminolevulinate
Trial: NCT00241124
Drug: valsartan
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00241124
Drug: lisinopril
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04092725
Drug: SCY-078 plus DAB
RxNorm normalized name: SCY-635
DrugBank: SCY-635 (DB12451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily (BID), every 12 hours (Q12H) oral doses of SCY-078 750 mg on Day 1 and Day 2; and single oral AM doses of SCY-078 750 mg on Day 3 and Day 4. On Day 3 a single 150-mg dose of DAB will be administered one hour after the AM dose of SCY-078.